Upfront versus deferred cytoreductive nephrectomy following targeted or immunotherapy: a population-based propensity score-matched analysis of perioperative complications

被引:1
作者
Ditonno, Francesco [1 ,2 ]
Bologna, Eugenio [1 ,3 ]
Licari, Leslie Claire [1 ,3 ]
Franco, Antonio [1 ,4 ]
Pettenuzzo, Greta [2 ,5 ]
Leonardo, Costantino [6 ]
Proietti, Flavia [6 ]
Carbonara, Umberto [7 ]
Mir, M. Carmen [8 ]
Crivellaro, Simone [5 ]
Veccia, Alessandro [2 ]
Bertolo, Riccardo [2 ]
Antonelli, Alessandro [2 ]
Autorino, Riccardo [1 ]
机构
[1] Rush Univ, Med Ctr, Dept Urol, 1725 W Harrison St,Suite 970, Chicago, IL 60612 USA
[2] Univ Verona, Azienda Ospedaliera Univ Integrata Verona, Dept Urol, Verona, Italy
[3] Sapienza Univ Rome, Policlin Umberto Hosp 1, Dept Maternal Child & Urol Sci, Rome, Italy
[4] Sapienza Univ, St Andrea Hosp, Dept Urol, Rome, Italy
[5] Univ Illinois, Dept Urol, Chicago, IL USA
[6] Regina Elena Inst Canc Res, Dept Urol, Rome, Italy
[7] Royal Surrey HNS Trust, Dept Urol, Guildford, England
[8] Hosp Univ Ribera, Dept Urol, Valencia, Spain
关键词
Cytoreductive surgery; Immune Checkpoint inhibitors; Kidney cancer; Nephrectomy; Postoperative complications; Tyrosine kinase inhibitors; RENAL-CELL CARCINOMA; THERAPY; NIVOLUMAB; SUNITINIB;
D O I
10.1007/s00345-024-05156-1
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose To evaluate the incidence of postoperative complications after cytoreductive nephrectomy (CN) following first-line treatment for metastatic renal cell carcinoma (mRCC), and to compare it with postoperative complications of upfront CN. Methods For this population-based retrospective study, the PearlDiver Mariner database (PearlDiver Technologies, Colorado Springs, CO), a database of insurance billing records was analyzed. Using relevant ICD-9/10 and CPT codes, patients diagnosed with mRCC between 2011 and 2021, who received first-line systemic molecular therapy (SMT), either tyrosine kinase inhibitors (TKI) or immune-checkpoint inhibitors (ICI), were identified. The selected population was stratified into two cohorts according to the timing of CN (deferred: after SMT vs. upfront: before SMT). Propensity-score matching (PSM) was performed as per baseline patients' characteristics to control for potential confounders between the two cohorts. The primary outcome was to compare 30-day postoperative complications rate between patients undergoing upfront vs. deferred CN. Results After PSM, 162 patients who received upfront CN were compared with 162 patients who underwent deferred CN. The overall rate of 30-day postoperative complications was statistically significantly higher in patients undergoing deferred CN (33.9%), compared to patients treated with upfront CN (21%, p < 0.01). In addition, the rate of both medical (26.5% vs. 14.2%, p < 0.01) and surgical (14.8 vs. 7.4%, p = 0.03) complication rate was statistically significantly higher in deferred vs. upfront CN. Multivariable logistic regression analysis revealed that none of the treatment regimens significantly predicted the occurrence of postoperative complications. Conclusion Patients undergoing deferred CN experience a higher rates of overall, medical, and surgical 30-day postoperative complications compared to those receiving upfront surgery. Findings from this study should be interpreted within the limitations of this type of analysis.
引用
收藏
页数:7
相关论文
共 35 条
[1]   The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014 [J].
Ascierto, Paolo A. ;
Addeo, Raffaele ;
Carteni, Giacomo ;
Daniele, Bruno ;
De Laurentis, Michele ;
Ianniello, Giovanni Pietro ;
Morabito, Alessandro ;
Palmieri, Giovannella ;
Pepe, Stefano ;
Perrone, Francesco ;
Pignata, Sandro ;
Montesarchio, Vincenzo .
JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12
[2]   Guidelines for Reporting of Statistics for Clinical Research in Urology [J].
Assel, Melissa ;
Sjoberg, Daniel ;
Elders, Andrew ;
Wang, Xuemei ;
Huo, Dezheng ;
Botchway, Albert ;
Delfino, Kristin ;
Fan, Yunhua ;
Zhao, Zhiguo ;
Koyama, Tatsuki ;
Hollenbeck, Brent ;
Qin, Rui ;
Zahnd, Whitney ;
Zabor, Emily C. ;
Kattan, Michael W. ;
Vickers, Andrew J. .
EUROPEAN UROLOGY, 2019, 75 (03) :358-367
[3]   Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium [J].
Bakouny, Ziad ;
El Zarif, Talal ;
Dudani, Shaan ;
Wells, J. Connor ;
Gan, Chun Loo ;
Donskov, Frede ;
Shapiro, Julia ;
Davis, Ian D. ;
Parnis, Francis ;
Ravi, Praful ;
Steinharter, John A. ;
Agarwal, Neeraj ;
Alva, Ajjai ;
Wood, Lori ;
Kapoor, Anil ;
Morales, Jose M. Ruiz ;
Kollmannsberger, Christian ;
Beuselinck, Benoit ;
Xie, Wanling ;
Heng, Daniel Y. C. ;
Choueiri, Toni K. .
EUROPEAN UROLOGY, 2023, 83 (02) :145-151
[4]  
Bex A, 2019, JAMA ONCOL, V5, P164, DOI 10.1001/jamaoncol.2018.5543
[5]   Neoadjuvant therapy for localized and locally advanced renal cell carcinoma [J].
Bindayi, Ahmet ;
Hamilton, Zachary A. ;
McDonald, Michelle L. ;
Yim, Kendrick ;
Millard, Frederick ;
McKay, Rana R. ;
Campbell, Steven C. ;
Rini, Brian I. ;
Derweesh, Ithaar H. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (01) :31-37
[6]   Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].
Choueiri, T. K. ;
Powles, T. ;
Burotto, M. ;
Escudier, B. ;
Bourlon, M. T. ;
Zurawski, B. ;
Juarez, V. M. Oyervides ;
Hsieh, J. J. ;
Basso, U. ;
Shah, A. Y. ;
Suarez, C. ;
Hamzaj, A. ;
Goh, J. C. ;
Barrios, C. ;
Richardet, M. ;
Porta, C. ;
Kowalyszyn, R. ;
Feregrino, J. P. ;
Zolnierek, J. ;
Pook, D. ;
Kessler, E. R. ;
Tomita, Y. ;
Mizuno, R. ;
Bedke, J. ;
Zhang, J. ;
Maurer, M. A. ;
Simsek, B. ;
Ejzykowicz, F. ;
Schwab, G. M. ;
Apolo, A. B. ;
Motzer, R. J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) :829-841
[7]   Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial [J].
Courcier, Jean ;
Dalban, Cecile ;
Laguerre, Brigitte ;
Ladoire, Sylvain ;
Barthelemy, Philippe ;
Oudard, Stephane ;
Joly, Florence ;
Gravis, Gwenaelle ;
Chevreau, Christine ;
Geoffrois, Lionel ;
Deluche, Elise ;
Rolland, Frederic ;
Topart, Delphine ;
Culine, Stephane ;
Negrier, Sylvie ;
Mahammedi, Hakim ;
Tantot, Florence ;
Jamet, Antoine ;
Escudier, Bernard ;
Flippot, Ronan ;
Albiges, Laurence .
EUROPEAN UROLOGY, 2021, 80 (03) :325-329
[8]   Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data [J].
de Bruijn, Roderick ;
Wimalasingham, Akhila ;
Szabados, Bernadett ;
Stewart, Grant D. ;
Welsh, Sarah J. ;
Kuusk, Teele ;
Blank, Christian ;
Haanen, John ;
Klatte, Tobias ;
Staehler, Michael ;
Powles, Thomas ;
Bex, Axel .
EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (02) :168-173
[9]   The immunology of renal cell carcinoma [J].
Diaz-Montero, C. Marcela ;
Rini, Brian I. ;
Finke, James H. .
NATURE REVIEWS NEPHROLOGY, 2020, 16 (12) :721-735
[10]  
Ghoreifi A, 2023, JAMA Oncol